AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. VTYX
  4. [SCHEDULE 13G/A] Ventyx Biosciences, Inc. SEC Filing

[SCHEDULE 13G/A] Ventyx Biosciences, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock VTYX logo
Ventyx Biosciences, Inc.

NASDAQ:VTYX

VTYX Rankings

#5921 Ranked by Market Cap
N/A Ranked by Dividends

VTYX Latest News

Aug 7, 2025
Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Jun 17, 2025
Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson鈥檚 Disease
May 28, 2025
Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference
May 8, 2025
Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Apr 1, 2025
Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

VTYX Latest SEC Filings

Aug 7, 2025
[8-K] Ventyx Biosciences, Inc. Reports Material Event

VTYX Stock Data

183.60M
68.23M
4.12%
74.35%
6.98%
Biotechnology
Pharmaceutical Preparations
United States
SAN DIEGO